Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah K Knutson

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
The EMBO Journal|March 21, 2008
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networksSarah K Knutson, Brenda J Chyla, Joseph M Amann, et al.
Molecular Cell|April 15, 2008
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage controlSrividya Bhaskara, Brenda J Chyla, Joseph M Amann, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2010
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasChristopher J Sneeringer, Margaret Porter Scott, Kevin W Kuntz, et al.
FEBS Letters|August 23, 2011
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation statesTim J Wigle, Sarah K Knutson, Lei Jin, et al.
Plos One|July 15, 2010
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fatDavid F Razidlo, Tiffany J Whitney, Michelle E Casper, et al.
FEBS Letters|August 2, 2012
A687V EZH2 is a gain-of-function mutation found in lymphoma patientsChristina R Majer, Lei Jin, Margaret Porter Scott, et al.
ACS Chemical Biology|August 26, 2014
Reaction coupling between wild-type and disease-associated mutant EZH2Brooke M Swalm, Sarah K Knutson, Natalie M Warholic, et al.
The Journal of Clinical Investigation|June 14, 2024
Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteinsMeng-Hsiung Hsieh, Yonglong Wei, Lin Li, et al.
Molecular Cancer Therapeutics|March 16, 2017
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical ModelsElayne Chan-Penebre, Kelli Armstrong, Allison Drew, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 27, 2013
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Sarah K Knutson, Natalie M Warholic, Tim J Wigle, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
The EMBO Journal|March 21, 2008
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networksSarah K Knutson, Brenda J Chyla, Joseph M Amann, et al.
Molecular Cell|April 15, 2008
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage controlSrividya Bhaskara, Brenda J Chyla, Joseph M Amann, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2010
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasChristopher J Sneeringer, Margaret Porter Scott, Kevin W Kuntz, et al.
FEBS Letters|August 23, 2011
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation statesTim J Wigle, Sarah K Knutson, Lei Jin, et al.
Plos One|July 15, 2010
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fatDavid F Razidlo, Tiffany J Whitney, Michelle E Casper, et al.
FEBS Letters|August 2, 2012
A687V EZH2 is a gain-of-function mutation found in lymphoma patientsChristina R Majer, Lei Jin, Margaret Porter Scott, et al.
ACS Chemical Biology|August 26, 2014
Reaction coupling between wild-type and disease-associated mutant EZH2Brooke M Swalm, Sarah K Knutson, Natalie M Warholic, et al.
The Journal of Clinical Investigation|June 14, 2024
Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteinsMeng-Hsiung Hsieh, Yonglong Wei, Lin Li, et al.
Molecular Cancer Therapeutics|March 16, 2017
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical ModelsElayne Chan-Penebre, Kelli Armstrong, Allison Drew, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 27, 2013
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Sarah K Knutson, Natalie M Warholic, Tim J Wigle, et al.
Pageof 3